Literature DB >> 3305080

Is it useful to remove internal mammary nodes in operable breast cancer?

J Lacour, M G Lê, C Hill, A Kramar, G Contesso, D Sarrazin.   

Abstract

From September 1963 to January 1968, 243 patients with operable breast cancer were included in a randomized trial designed to compare classical radical mastectomy (RM) alone to extended mastectomy (EM), i.e. RM plus internal mammary dissection. One hundred and seventeen patients underwent RM, and 126 EM. After a mean follow-up time of 20 years, no significant differences were observed between the two treatment groups for overall survival, for the relapse-free survival rates, nor for distant metastasis, or locoregional recurrence rates. From a regression model, significant interactions were found between risk of death, EM, and both nodal status and site of the tumour. When compared to RM, EM significantly decreased the risk of death for patients with internal or medial tumour and positive axillary nodes (P = 0.05). No beneficial effect of EM was observed for any of the other patients; on the contrary, EM seemed to increase the risk of death for the patients with external tumour and negative axillary nodes (P = 0.07).

Entities:  

Mesh:

Year:  1987        PMID: 3305080

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  19 in total

1.  Controversies in the Surgical Management of Operable Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

2.  Have changing treatment patterns affected outcome for operable breast cancer? Ten-year follow-up in 1288 patients, 1965 to 1978.

Authors:  H S Cody; E H Laughlin; C Trillo; J A Urban
Journal:  Ann Surg       Date:  1991-04       Impact factor: 12.969

3.  Intramammary sentinel lymph node in patients with breast cancer: report of four cases.

Authors:  Yuko Kijima; Heiji Yoshinaka; Yoshikazu Uenosono; Yawara Funasako; Katsuhiko Ehi; Shigehiro Yanagita; Hideo Arima; Tsutomu Kozono; Takaaki Arigami; Shoji Natsugoe; Takashi Aikou
Journal:  Surg Today       Date:  2008-05-31       Impact factor: 2.549

4.  Unintended irradiation of internal mammary chain - Is that enough?

Authors:  Lucas Gomes Sapienza; Michael Jenwei Chen; Maria José Leite Gomes; David B Mansur
Journal:  Rep Pract Oncol Radiother       Date:  2015-08-11

5.  Clinically apparent internal mammary nodal metastasis in patients with advanced breast cancer: incidence and local control.

Authors:  Yu-Jing Zhang; Julia L Oh; Gary J Whitman; Puneeth Iyengar; Tse-Kuan Yu; Welela Tereffe; Wendy A Woodward; George Perkins; Thomas A Buchholz; Eric A Strom
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-12-11       Impact factor: 7.038

Review 6.  Natural history of human breast cancer: recent data and clinical implications.

Authors:  M Tubiana; S Koscielny
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

7.  Internal mammary node status: a major prognosticator in axillary node-negative breast cancer.

Authors:  H S Cody; J A Urban
Journal:  Ann Surg Oncol       Date:  1995-01       Impact factor: 5.344

8.  Radical mastectomy with parasternal node dissection or radiation to the parasternal region for breast cancer of medial or central location.

Authors:  E Shiba; K Miyauchi; T Kobayashi; S Takai; T Mori
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

9.  Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer.

Authors:  José M del Casar; Guillermo Carreño; Luis O González; Sara Junquera; Salomé González-Reyes; José M González; Miguel Bongera; Antonio M Merino; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-30       Impact factor: 4.553

10.  Medial tumor localization in breast cancer--an unappreciated risk factor?

Authors:  Elisabeth Bräutigam; Christine Track; Dietmar H Seewald; Johann Feichtinger; Kurt Spiegl; Josef Hammer
Journal:  Strahlenther Onkol       Date:  2009-10-06       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.